AzTrials
AzTrials

Adhesive Capsulitis of ShoulderNCT02461368

Ultrasound-Guided Glenohumeral Steroid Injection

A study testing Glenohumeral triamcinolone injection by anterior approach and Glenohumeral triamcinolone injection by posterior approach in people with Adhesive Capsulitis of Shoulder, run by Chuncheon Sacred Heart Hospital at 1 site in South Korea.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators compared the results of the ultrasound-guided anterior and posterior approaches to administer glenohumeral steroid injections to patients with primary adhesive capsulitis of the shoulder joint by a single experienced provider. Read more about this study

Who is it for?
Ages 20 to 80 years
Conditions the study is for
Adhesive Capsulitis of Shoulder
What is being tested?
Glenohumeral triamcinolone injection by anterior approach and Glenohumeral triamcinolone injection by posterior approach
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteSouth Korea
Study dates
Dec 2012to Feb 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • shoulder pain and limitations of active and passive motion in at least two directions (abduction and forward flexion < 100, external rotation < 30, or internal rotation < L3) on the pre-injection check-up
  • those who underwent MRI or ultrasonography with no secondary cause for adhesive capsulitis, such as a rotator cuff tear, calcific tendinitis, or osteoarthritis

Who cannot join

  • history of fracture or operation on the affected shoulder
  • loss to follow-up before 13 weeks after the injection
  • receiving another treatment that was different from our protocol within 13 weeks after the injection
  • no functional scores within 13 weeks after the injection

Trial locations and contacts

1 site in 1 country.

South Korea1 site
  • Chuncheon Sacred Heart Hospital

    Chuncheon, Gangwon-do, 700-204

Other trials in South Korea

About this study

Official title: Comparison Between Anterior and Posterior Approaches for Ultrasound-guided Glenohumeral Steroid Injection: A Randomized Controlled Trial

The investigators compared the results of the ultrasound-guided anterior and posterior approaches to administer glenohumeral steroid injections to patients with primary adhesive capsulitis of the shoulder joint by a single experienced provider.

Read the detailed description

This study was a randomized controlled trial of 50 patients, who underwent history taking, physical examinations, x-rays, and MRI or ultrasonography, and were diagnosed with primary adhesive capsulitis of the shoulder from December 2012 to November 2013. The 50 patients were assigned to Group I (anterior approach) or Group II (posterior approach) under double-blinded randomization. The randomization was performed by an independent nurse using a computerized random sequence generator. The operators who participated in the procedure were blinded to the participant's information. The injection mixture for both groups was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare). After the injection, anteroposterior, scapular lateral, and axillary x-rays of the shoulder were taken of all patients within 15 min, and leakage was classified into three categories by a musculoskeletal radiologist with 18 years experience: 1) no leakage; 2) leakage; and 3) cannot be determined. Injection accuracy was defined as [number of 1) ÷ {number of 1) + number of 2) + number of 3)}] × 100 (%). The frequency of needling until the injection had been completed was checked. A visual analog scale (VAS) for pain, range of motion (ROM), patient's satisfaction (SAT), the American Shoulder and Elbow Surgeons (ASES) shoulder score, and the Constant score were recorded before, and 3, 7, and 13 weeks after the injection. VAS scores range from 0 to 10, with 0 being no pain and 10 being the most severe pain ever experienced. Internal rotation was measured from buttock to T5 in this study, with the range between L5 and T5 being allocated a sequential value between 2 and 13 and the range below the first sacral vertebra being allocated 1. SAT was also selected from a scale of 0 to 10, with 0 being unsatisfactory and 10 being very satisfactory. Stick exercises were started at 3 weeks, and theraband exercises were started 7 weeks after the injection.

Two patients of 54 patients who had been assessed for eligibility in this study were excluded due to proximal humerus fractures of the affected shoulders. And another two participants were excluded because they had declined to participate. One Group I patient was excluded due to an additional subacromial injection 3 weeks after the study injection. And another Group I patient was excluded due to loss of follow-up before 13 weeks. Also, two patients were excluded from Group II because of loss to follow-up. Finally, 46 patients were included in the study (n = 23/group). The demographic data of the two groups were not significantly different.

Diagnostic ultrasonography was performed by a musculoskeletal radiologist with 18 years experience using ultrasound (Philips Healthcare) before the injection. The ultrasound-guided glenohumeral steroid injection was administered by a shoulder and elbow surgeon who performed more than 2,000 similar procedures.

A 21-gauge spinal needle was used for all of the ultrasound-guided steroid injections. The patient was supine with the shoulder slightly rotated externally for the anterior approach. The shoulder was draped in sterile fashion using 70% alcohol and povidone-iodine solution. The linear ultrasonography probe (General Electronics Healthcare) was prepared with 70% alcohol and a thin layer of sterile ultrasonographic transmission gel (Republic of Korea). The needle was inserted at the level of the coracoids, from lateral to medial, and was aimed at the medial border of the humeral head, parallel to the longitudinal axis of the probe. The posterior approach was performed with the patient in the lateral decubitus position on the unaffected side, leaning 45 degree anteriorly and hugging a pillow. The needle was inserted from lateral to medial, parallel to the longitudinal axis of the probe, and into the joint between the humeral head and the posterior glenoid labrum.

The participants took off their coats and shirts in the injection room. Females wore a skirt at the axillary level exposing the shoulder for injection. The provider entered the injection room and positioned the patients appropriately. Just after positioning, the operator put on gloves, prepared the injection mixture, and administered the injection. Positioning time (from operator entering the room until the end of positioning) and injection time (from putting on gloves until just after the injection) were recorded by an independent nurse. The sum of the two times was recorded as the total time, and the frequency of needling during the injection for one patient was also recorded.

A power analysis indicated that a sample size of 46 patients (23/group) would provide a statistical power of 80%, with a two-sided α level of 0.05 to detect a significant difference in the improvement of ASES score between initial and 13 weeks after injection, assuming an effect size of 0.85 (mean difference, 16.1; standard deviation, 19.0). This was based on the mean and standard deviation of the improvement of ASES score between initial and 13 weeks after injection observed in a pilot study of 20 patients.

The Wilcoxon signed-rank test was used to compare preoperative and postoperative data. Normally distributed data between the groups were analyzed using the independent sample t-test. Otherwise, the nonparametric Mann-Whitney U-test was used. Statistical analyses were performed with SPSS ver. 13.0 software (SPSS Inc., Chicago, USA). A p value < 0.05 was considered statistically significant.

Being tested
Glenohumeral triamcinolone injection by anterior approach, Glenohumeral triamcinolone injection by posterior approach
Medical subject headings
Bursitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Glenohumeral triamcinolone injection by anterior approachProcedure or surgery

    Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).

  • Glenohumeral triamcinolone injection by posterior approachProcedure or surgery

    Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).

Study groups in NCT02461368
Study groupRoleWhat they receive
anterior approachExperimentalUltrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Receives: Procedure: Glenohumeral triamcinolone injection by anterior approach
posterior approachActive comparatorUltrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
Receives: Procedure: Glenohumeral triamcinolone injection by posterior approach

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. visual analog scale (VAS) for pain

    0-10, 0: no pain, 10: very severe pain

    Measured: initial, Week 3, 7, 13

  2. range of motion (ROM)

    degree

    Measured: initial, Week 3, 7, 13

  3. patient's satisfaction (SAT)

    0-10, 0: not satisfied, 10: very much satisfied

    Measured: initial, Week 3, 7, 13

  4. American Shoulder and Elbow Surgeons (ASES) shoulder score

    0-100

    Measured: initial, Week 3, 7, 13

  5. Constant score

    0-100

    Measured: initial, Week 3, 7, 13

Secondary outcomes (1)
  1. Accuracy of injection using post-injection X-ray

    Injection material includes 3cc Omnipaque, therefore, the accuracy of injection can be checked just after the injection. After the injection, anteroposterior, scapular lateral, and axillary x-rays of the shoulder were taken of all patients within 15 min, and leakage was classified into three categories by a musculoskeletal radiologist with 18 years experience: 1) no leakage; 2) leakage; and 3) cannot be determined.

    Measured: within 15 minutes after injection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jun 2015 (estimated)
  2. Study startDec 2012
  3. Primary completionNov 2013
  4. Study completionFeb 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02461368
Sponsor's protocol ID
GH injection
Status last verified
Sep 2023
First submitted
29 May 2015
Last updated
22 Sep 2023
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Glenohumeral triamcinolone injection by anterior approach and Glenohumeral triamcinolone injection by posterior approach in people with Adhesive Capsulitis of Shoulder, run by Chuncheon Sacred Heart Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

visual analog scale (VAS) for pain (time frame: initial, Week 3, 7, 13). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in